← Back to Screener
Abeona Therapeutics Inc. Common Stock (ABEO)
Price$5.38
Favorite Metrics
Price vs S&P 500 (26W)-6.51%
Price vs S&P 500 (4W)12.86%
Market Capitalization$306.92M
P/E Ratio (Annual)4.31x
All Metrics
Book Value / Share (Quarterly)$2.89
P/TBV (Annual)1.98x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)60.41%
Cash Flow / Share (Quarterly)$-1.53
Price vs S&P 500 (YTD)-0.18%
Gross Margin (TTM)80.74%
Net Profit Margin (TTM)1518.44%
EPS (TTM)$0.93
10-Day Avg Trading Volume1.23M
EPS Excl Extra (TTM)$0.93
Revenue Growth (5Y)-10.26%
EPS (Annual)$1.08
ROI (Annual)39.71%
Gross Margin (Annual)73.68%
Net Profit Margin (5Y Avg)-1362.88%
Cash / Share (Quarterly)$3.48
P/E Basic Excl Extra (TTM)4.31x
P/E Normalized (Annual)4.31x
ROA (Last FY)32.42%
EBITD / Share (TTM)$1.28
ROE (5Y Avg)-155.78%
Operating Margin (TTM)1832.70%
Cash Flow / Share (Annual)$-1.53
P/B Ratio1.93x
P/B Ratio (Quarterly)1.79x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)42.70x
Net Interest Coverage (TTM)-127.06x
ROA (TTM)35.76%
EV / EBITDA (TTM)3.45x
EPS Incl Extra (Annual)$1.08
Current Ratio (Annual)6.93x
Quick Ratio (Quarterly)6.70x
3-Month Avg Trading Volume1.23M
52-Week Price Return9.09%
P/E Incl Extra (TTM)4.31x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.51
P/S Ratio (Annual)52.74x
Asset Turnover (Annual)0.03x
52-Week High$7.54
Operating Margin (5Y Avg)-1525.44%
EPS Excl Extra (Annual)$1.08
CapEx CAGR (5Y)42.86%
Tangible BV CAGR (5Y)-30.62%
26-Week Price Return-2.53%
Quick Ratio (Annual)6.70x
13-Week Price Return5.88%
Total Debt / Equity (Annual)0.13x
Current Ratio (Quarterly)6.93x
Enterprise Value$248.522
Revenue / Share Growth (5Y)-49.56%
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)-36.03%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.30x
Pretax Margin (Annual)1224.79%
Cash / Share (Annual)$3.48
3-Month Return Std Dev45.01%
Gross Margin (5Y Avg)90.75%
Net Income / Employee (TTM)$1
ROE (Last FY)44.71%
Net Interest Coverage (Annual)-242.28x
EPS Basic Excl Extra (Annual)$1.08
P/FCF (TTM)176.39x
Receivables Turnover (TTM)1.59x
Total Debt / Equity (Quarterly)0.13x
EPS Incl Extra (TTM)$0.93
Receivables Turnover (Annual)0.94x
ROI (TTM)46.37%
P/S Ratio (TTM)52.74x
Pretax Margin (5Y Avg)-1362.53%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$1.51
Forward P/E4.32x
Price vs S&P 500 (52W)-20.74%
P/E Ratio (TTM)4.31x
Year-to-Date Return2.47%
5-Day Price Return5.47%
EPS Normalized (Annual)$1.08
ROA (5Y Avg)-55.86%
Net Profit Margin (Annual)1223.08%
Month-to-Date Return20.54%
Cash Flow / Share (TTM)$-1.97
EBITD / Share (Annual)$1.09
Operating Margin (Annual)1081.07%
LT Debt / Equity (Annual)0.05x
ROI (5Y Avg)-148.07%
P/E Excl Extra (TTM)4.31x
LT Debt / Equity (Quarterly)0.05x
EPS Basic Excl Extra (TTM)$0.93
P/TBV (Quarterly)1.98x
P/B Ratio (Annual)1.79x
Inventory Turnover (TTM)1.30x
Pretax Margin (TTM)1781.27%
Book Value / Share (Annual)$2.89
Price vs S&P 500 (13W)5.19%
Beta1.32x
Revenue / Share (TTM)$0.11
ROE (TTM)53.18%
52-Week Low$4.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ABEOAbeona Therapeutics Inc. Common Stock | 52.74x | — | 80.74% | — | $5.38 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Abeona Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies and plasma-based treatments for rare genetic diseases with significant unmet medical needs. The company's pipeline includes pz-cel, an autologous cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB), and adeno-associated virus (AAV)-based gene therapies for rare ophthalmic diseases. These programs target patient populations with limited treatment options and substantial commercial potential.